Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects

Completed · Phase 2

Conditions studied: Opioid Related Disorder

In brief

This is an open-label study in treatment seeking opioid-dependent subjects for safety, tolerability, pharmacokinetics (PK), efficacy markers, and opioid receptor availability of subcutaneous injections of depot buprenorphine after induction and stabilization of treatment seeking subjects onto Subutex. Subjects were planned to receive 4 subcutaneous (SC) injections of RBP-6000 separated by 28 days (Cohorts 1-5) or 6 SC injections of RBP-6000 separated by 28 days (Cohort 6) after a 13-day induction and dose stabilisation period on SUBUTEX Sublingual (SL) tablet at dose levels of 8-24 mg.

Key facts

Study ID

NCT01738503

Run by

Indivior Inc.

People needed

124

Starts

2012-10-01

Expected to finish

2014-05-01

Last updated by the study team

2018-02-23

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female subjects
• Agree not to take any buprenorphine products other than those administered for the current study throughout participation in the study
• Body mass index (BMI) of >18.0 to < 33.0 kg/m

You may not qualify if…

• Participants with a current diagnosis requiring chronic opioid treatment
• Participants with a history of risk factors of Torsades de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) or an ECG demonstrating a Fridericia's corrected QT interval (QTcF) >450 msec in males and QTcF > 470 in females at screening
• Abuse of buprenorphine or use of buprenorphine within 14 days of informed consent

Where it is running

• Vince and Associates Clinical Research — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.